Linezolid-induced Thrombocytopenia and Anaemia in a Patient with Multidrug- resistant Tuberculosis: A Case Report

Linezolid is a new class of antimicrobials with excellent safety and efficacy profiles and has been suggested as a promising alternative to treat patients with multidrug-resistant tuberculosis or extensively drug-resistant TB. While being effective in managing strains, Linezolid eventually induces haematological side effects such as severe thrombocytopenia, anaemia and leukopenia after 2 weeks of therapy. Understanding the risks of linezolid is crucial for optimising patient outcomes and minimising adverse reactions. The case of a 37-year-old female who was diagnosed with multidrug-resistant tuberculosis and was being treated with linezolid was presented. Later, the patient developed severe haematological complications as observed in laboratory investigation (haemoglobin 2.9 g/dl (12-15 g/dl), Platelet count 35 x103/mm3(150-410 x103/mm3) following cessation of linezolid, the patient’s haematological parameters gradually improved and conditions resolved.